What is the approximate health insurance price of dabrafenib? Can it be reimbursed?

Under the current trend of continuous improvement of China's medical system and the gradual inclusion of anti-cancer drugs into medical insurance, dabrafenib, as a representative targeted therapy drug, has been officially introduced into the country and successfully included in the medical insurance catalog. The original drug dabrafenib was developed by Novartis Pharmaceuticals. It is mainly used to treat advanced melanoma with BRAF V600E mutation and some non-small cell lung cancer and other malignant tumors. It belongs to the BRAF kinase inhibitor class of drugs, and its clinical value has been internationally recognized.

Currently, the common specifications of dabrafenib in the domestic market are There are two versions of 50 mg and 75 mg. Each box is packed with 120 pills. A complete treatment cycle requires continuous medication. Calculated based on the original price, the market price of each box may be between 12,000 and 15,000 yuan, making it a high-value drug. However, after being included in medical insurance, the patient's financial burden is significantly reduced, especially in the case of hospitalization or outpatient special diseases, which can be reimbursed according to medical insurance policies ranging from 60% to 90%. The reimbursement ratio and actual cost will vary depending on the province and the specific type of medical insurance (employee medical insurance or resident medical insurance). For example, some cities have incorporated it into the long-term management of specific diseases in outpatient clinics, and patients only need to bear a lower proportion of out-of-pocket expenses, which greatly improves the accessibility of medication.

In addition, the national medical insurance negotiation mechanism also plays a key role in the price formation of this drug, which is especially important for patient groups who rely on this drug to maintain disease control for a long time. In terms of payment channels, you can not only obtain medical insurance reimbursement through the hospital, but also make overall settlement according to the medical insurance through the pharmacy, making it convenient to purchase medicines. Therefore, for patients with BRAF mutation-related cancers, dabrafenib not only represents a more precise treatment strategy, but also gradually moves towards affordable treatment, and its medical insurance coverage has brought substantial benefits to patients. With further optimization of drug policies, it is expected that its accessibility in primary care will continue to increase in the future.

Reference materials:https://go.drugbank.com/drugs/DB08912